多发性硬化症补充系统的贡献:机制和治疗潜力
Runjing Cao1, Li-Wen Zhu2, Bo Chen1
1Center for Rehabilitation Medicine, Department of Neurology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Zhejiang, Hangzhou, China.
Immunology
|April 16, 2025
概括
补体系统在多发性硬化症 (MS) 发病过程中起着复杂的作用. 了解它的途径和组件可能会导致新的MS疗法和诊断生物标志物.
科学领域:
- 免疫学 免疫学 免疫学
- 神经科学是一个神经科学.
背景情况:
- 补体系统对于先天性和适应性免疫是至关重要的.
- 多发性硬化症 (MS) 是一种中枢神经系统自身免疫性疾病,涉及髓破坏.
研究的目的:
- 审查补充系统在多发性硬化症 (MS) 发病过程中的作用.
- 探索补充成分作为MS诊断和预后的潜在生物标志物.
主要方法:
- 关于MS中补充系统参与的文献审查.
- 分析使用淘汰赛小鼠模型的研究.
- 在多发性硬化患者样本 (大脑,血液,脑脊髓液) 中检查补充成分表达.
主要成果:
- 补充成分在多发性硬化患者的组织和液体中高度表达.
- 研究表明,补充剂在多发性硬化症的发病过程中的作用存在争议.
- 类毒素C3a和C5a有助于MS病理.
结论:
- 补体系统在MS病理学中起着重要作用.
- 补充成分显示出作为MS预测和评估的生物标志物的潜力.
- 进一步了解可能会指导MS的新疗法策略.
相关概念视频
T Cell Types and Functions
633
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
633
Mesenchymal Stem Cells
4.6K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.6K
Myasthenia Gravis: Overview and Treatment
980
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
980


